Skip to main content
295 search results for:

SGLT2 inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 10-06-2022 | SGLT2 inhibitors | News | Article
    News in brief

    SGLT2 inhibitors linked to lower gout risk than DPP-4 inhibitors

    SGLT2 inhibitors are associated with a lower risk for gout than DPP-4 inhibitors, research suggests.

  2. 11-08-2022 | SGLT2 inhibitors | News | Article

    Meta-analysis backs SGLT2 inhibitors for kidney disease

    A meta-analysis published in The Lancet supports the use of SGLT2 inhibitors in people with chronic kidney disease, irrespective of whether they have type 2 diabetes.

  3. 10-04-2022 | Healthcare costs | News | Article

    First-line SGLT2 inhibitors, GLP-1 receptor agonists ‘not cost effective’

    The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.

  4. 06-07-2022 | ADA 2022 | News | Article

    Case series suggests SGLT2 inhibitors could be useful add-on therapy for MODY3

    Results from a small case series in Denmark suggest SGLT2 inhibitors could be a useful add-on therapy for people with maturity-onset diabetes of the young.

  5. 09-21-2021 | Hypoglycemia | View from the clinic | Article

    Hypoglycemia in people taking alpha-glucosidase inhibitors

    Sanjay Kalra explains how use of alpha-glucosidase inhibitors in people with type 2 diabetes can complicate the treatment of hypoglycemia.

  6. 02-04-2022 | Cardiovascular outcomes | News | Article

    Real-world data support SGLT2 inhibitors, GLP-1 receptor agonists for primary CVD prevention

    Data from primary care suggest that use of sodium-glucose cotransporter2 inhibitors, and possibly glucagon-like peptide-1 receptor agonists, may reduce the risk for cardiovascular disease events in people with type 2 diabetes without previous events.

  7. 09-07-2021 | Nephropathy | Ask the expert | Article

    DKD treatment update: SGLT2 inhibitors and finerenone

    You've identified some areas where it's really expanded our on knowledge and excitement around the use of SGLT2 inhibitors, dapagliflozin in this particular instance.

  8. 10-01-2021 | EASD 2021 | News | Article

    Use of SGLT2 inhibitors beneficial in older adults with type 2 diabetes

    Among older people with type 2 diabetes, use of SGLT2 inhibitors is associated with improved glycemic control and a favorable safety profile, suggests research reported at the virtual 57th EASD Annual Meeting.

  9. 09-29-2021 | EASD 2021 | News | Article

    SUSTAIN 10 analysis supports additive benefits of GLP-1 receptor agonists, SGLT2 inhibitors

    A post-hoc analysis of SUSTAIN 10 indicates that people with type 2 diabetes stand to gain from GLP-1 receptor agonist use even if they are already using an SGLT2 inhibitor.

  10. 08-13-2021 | SGLT2 inhibitors | News | Article
    News in brief

    SGLT2 inhibitors linked to retinal vein occlusion in type 2 diabetes

    New users of SGLT2 inhibitors are more likely to develop retinal vein occlusion than those initiating other glucose-lowering drugs, suggest results from a South Korean study.

  11. 07-30-2021 | SGLT2 inhibitors | News | Article

    SGLT2 inhibitors linked to lower mortality rate than sulfonylureas in clinical practice

    Use of SGLT2 inhibitors rather than sulfonylureas as an addition to metformin therapy may be associated with a reduced mortality risk for people with type 2 diabetes, suggest real-world study findings.

  12. 05-17-2021 | ACC 2021 | News | Article

    DARE-19 supports continuing SGLT2 inhibitors in event of SARS-CoV-2 infection

    “Our results therefore do not support discontinuation of SGLT2 inhibitors in a setting of COVID-19, as long as patients are monitored,” said researcher Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, Kansas City, Missouri, USA).

  13. 03-29-2021 | Empagliflozin | News | Article

    Diuresis ‘not dominant’ mediator of SGLT2 inhibitors’ cardiac benefits

    But they found that people with clinical evidence of recent volume overload “do not exhibit an exaggerated benefit with SGLT2 inhibitors, even during short-term treatment,” suggesting that the diuretic effect of the treatment class is not the major mechanism underpinning its cardioprotective effects.

  14. 03-30-2021 | SGLT2 inhibitors | News | Article
    News in brief

    Treatment with SGLT2 inhibitors may reduce risk for kidney stones

    SGLT2 inhibitor treatment could lower the risk for incident and recurrent kidney stones in people with type 2 diabetes, suggest Danish study results.

  15. 02-08-2021 | COVID-19 | News | Article

    No need to discontinue DPP-4 inhibitors during hospitalization for COVID-19

    Results from the CORONADO study indicate that use of DPP-4 inhibitors does not affect outcomes for people with type 2 diabetes admitted to hospital with COVID-19.

  16. 10-07-2020 | EASD 2020 | Conference coverage | Article

    Acute eGFR decline with SGLT2 inhibitors does not affect outcome

    The benefits of treatment with SGLT2 inhibitors are not negated by the initial decline in estimated glomerular filtration rate commonly seen with these drugs, show post-hoc analyses of the EMPA-REG OUTCOME and CREDENCE trials.

  17. 10-02-2020 | COVID-19 | News | Article

    SGLT2 inhibitors unlikely to increase SARS-CoV-2 infection risk

    The incidence of COVID-19 is no higher among people taking SGLT2 inhibitors than those taking DPP-4 inhibitors, research shows.

  18. 06-29-2020 | SGLT2 inhibitors | News | Article

    CVD-REAL 2 data support cardiovascular benefits of SGLT2 inhibitors

    The latest CVD-REAL 2 data confirm clinical trial findings by showing that SGLT2 inhibitors significantly lower cardiovascular disease risk in people with type 2 diabetes, this time in comparison with DPP-4 inhibitors.

  19. 12-09-2019 | SGLT2 inhibitors | Channel

    SGLT2 inhibitors in type 2 diabetes management: Guidance from the Improving Diabetes Steering Committee

    The IDSC present their guidance on prescribing SGLT2 inhibitors to patients with common risk factors associated with type 2 diabetes, including CVD.

  20. 09-06-2018 | SGLT2 inhibitors | Patient and physician’s perspective | Article

    Living with type 2 diabetes: Patient commentary in response to the paper ‘SGLT2 inhibitors in type 2 diabetes management: Key evidence and implications for clinical practice’

    A patient discusses their experience of living with type 2 diabetes, including their experience of diagnosis and self-management, education and adoption of SGLT2 inhibitors to treat the disease.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.